KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) FCF Margin (2016 - 2025)

Historic FCF Margin for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to 31.73%.

  • Pacira BioSciences' FCF Margin rose 21700.0% to 31.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.33%, marking a year-over-year decrease of 105200.0%. This contributed to the annual value of 25.5% for FY2024, which is 48400.0% up from last year.
  • Per Pacira BioSciences' latest filing, its FCF Margin stood at 31.73% for Q3 2025, which was up 21700.0% from 5.14% recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' FCF Margin peaked at 36.96% during Q3 2021, and registered a low of 0.83% during Q1 2021.
  • Moreover, its 5-year median value for FCF Margin was 21.25% (2022), whereas its average is 19.25%.
  • Per our database at Business Quant, Pacira BioSciences' FCF Margin soared by 469300bps in 2021 and then crashed by -238700bps in 2025.
  • Over the past 5 years, Pacira BioSciences' FCF Margin (Quarter) stood at 8.83% in 2021, then skyrocketed by 141bps to 21.25% in 2022, then rose by 19bps to 25.26% in 2023, then plummeted by -34bps to 16.56% in 2024, then skyrocketed by 92bps to 31.73% in 2025.
  • Its last three reported values are 31.73% in Q3 2025, 5.14% for Q2 2025, and 15.93% during Q1 2025.